Revision 1

Store at -20C

#3793

CIITA Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Transfected Only	140	Rabbit	#P33076	4261

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

CIITA Antibody detects transfected levels of total CIITA protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu149 of human CIITA. Antibodies are purified by peptide affinity chromatography.

Background

MHC class II (MHC-II) proteins play critical roles in cellular immune responses and their expression is mainly regulated by the non-DNA binding transcription factor CIITA (MHC class II transactivator) (1,2). CIITA expression is upregulated by IFN-γ and it in turn enchances MHC-II expression and represses collagen expression (3,4). CIITA has a limited number of transcriptional targets, most of which are involved in MHC-mediated antigen presentation (5). Mutations in the CIITA are associated with the hereditary immunodeficiency disease Bare Lymphocyte Syndrome (BLS) which is characterized by a nearly complete absence of MHC-II expression (also referred to as MHC-II deficiency) (6,7).

Background References

1. Ting, J.P. and Trowsdale, J. (2002) *Cell* 109 Suppl, S21-33.
2. Drozina, G. et al. (2005) *Curr Top Microbiol Immunol* 290, 147-70.
3. Dong, Y. et al. (1999) *J Immunol* 162, 4731-9.
4. Butticè, G. et al. (2006) *Circ Res* 98, 472-9.
5. Krawczyk, M. et al. (2008) *PLoS Genet* 4, e1000058.
6. Reith, W. and Mach, B. (2001) *Annu Rev Immunol* 19, 331-73.
7. Waldburger, J.M. et al. (2000) *Immunol Rev* 178, 148-65.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.